AMRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Amneal Pharmaceuticals Inc (AMRX) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has positive long-term growth potential based on analyst ratings and EBITDA guidance, the current technical indicators and financial performance suggest a cautious approach. The lack of significant trading signals and the recent drop in net income and EPS further support a hold recommendation.
The MACD histogram is negative and contracting (-0.0257), indicating bearish momentum. The RSI is at 39.112, suggesting the stock is nearing oversold territory but not yet there. Moving averages are converging, showing no clear trend. The price is near the pivot point (12.119), with support at 11.802 and resistance at 12.436. Overall, technical indicators suggest a neutral to slightly bearish trend.
Analysts have raised price targets to $17, citing strong EBITDA growth guidance and solid Q4 results. The affordable medicines theme remains attractive for long-term growth. Gross margin increased slightly YoY, indicating operational efficiency.
Net income and EPS have significantly dropped YoY (-212.85% and -210.00%, respectively). The stock has shown a recent price decline (-1.63% in regular market trading). No recent news or significant trading trends from hedge funds, insiders, or Congress. Lack of strong trading signals from AI Stock Picker or SwingMax.
In Q4 2025, revenue increased by 11.47% YoY to $814.32M, showing growth in topline performance. However, net income dropped significantly to $35.08M (-212.85% YoY), and EPS declined to 0.11 (-210.00% YoY). Gross margin improved slightly to 36.5% (+1.45% YoY), but the sharp decline in profitability is a concern.
Analysts from Goldman Sachs, Truist, and JPMorgan have raised price targets to $17-$18, maintaining Buy or Overweight ratings. They highlight strong EBITDA growth guidance and solid Q4 results as key positives, but note softer GRx performance and slightly below-Street revenue guidance for FY26.
